secwatch.observer — SEC 8-K summary
======================================

Issuer:     Emmaus Life Sciences, Inc. (EMMA)
CIK:        0000822370
Form:       8-K
Filed at:   2024-09-10T23:59:59+00:00
Accession:  0001213900-24-077411
Event type: earnings
Sentiment:  negative
Materiality: 0.80
Item codes: 2.02, 4.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Revenue falls 55% to $7.9M, net loss $6.5M; auditor Baker Tilly declines reappointment
--------------------------------------------------------------------------------

- Net revenue for H1 2024 was $7.9M, down 55% from $17.5M in H1 2023, due to inventory shortages.
- Net loss of $6.5M ($0.10/sh) vs $5.0M ($0.10/sh) in prior year; operating loss $2.2M vs income $2.2M.
- Cash at June 30, 2024: $1.5M, down from $2.5M at Dec 31, 2023.
- CEO says full-year revenue unlikely to match 2023; generic L-Glutamine launch poses risk to Endari.
- Auditor Baker Tilly notified Sept 5, 2024 it will not stand for reappointment; no disagreements but prior reports include going concern note.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/822370/000121390024077411/0001213900-24-077411-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/822370/000121390024077411/ea021395101-8k_emmaus.htm
  HTML page:      https://secwatch.observer/filing/0001213900-24-077411

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer